Non‐thrombotic‐, non‐inhibitor‐associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand’s disease: a systematic review of prospective studies
- 18 January 2012
- journal article
- review article
- Published by Wiley in Haemophilia
- Vol. 18 (3), e164-e172
- https://doi.org/10.1111/j.1365-2516.2011.02745.x
Abstract
Summary. In the last three decades there have been dramatic improvements in the availability and quality of treatment for people with inherited coagulation disorders. Indeed, the improvement of methods of purification and viral inactivation for plasma‐derived coagulation factor concentrates first and then the development of products utilizing recombinant DNA technology have greatly improved the life expectancy of hemophiliacs, which has progressively become similar to that of males in the general population. Nowadays, the most frequent complication of factor replacement therapy for hemophilia is the development of inhibitors. However, no studies so far have systematically analysed the type and incidence of other adverse reactions following the administration of coagulation factor concentrates. The aim of this systematic review was to screen the published literature data to evaluate the types and frequencies of non‐thrombotic‐, non‐inhibitor‐associated adverse reactions to coagulation factor concentrates in patients with hemophilia A, hemophilia B and von Willebrand’s disease. On behalf the European Haemophilia Safety Surveillance System (EUHASS), a systematic review of the prospective studies published in the last 20 years was performed using electronic databases and article references. Both severe and mild adverse events following infusion of coagulation factor concentrates are relatively rare in patients with inherited coagulation disorders; the most common events are of an allergic type. There are no differences in the rate of adverse events caused by plasma‐derived or recombinant products. On the whole, these data confirm the high degree of safety of the products currently used for replacement therapy.Keywords
This publication has 71 references indexed in Scilit:
- Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practiceBritish Journal of Clinical Pharmacology, 2010
- Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practiceHaemophilia, 2010
- Postmarketing surveillance study of KOGENATE® Bayer with Bio‐Set® in patients with haemophilia A: evaluation of patients’ satisfaction after switch to the new reconstitution systemHaemophilia, 2009
- Plasma and albumin‐free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patientsJournal of Thrombosis and Haemostasis, 2008
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- ReFacto®1 and Advate®2: a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia AHaemophilia, 2007
- Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigationJournal of Thrombosis and Haemostasis, 2004
- Clinical Evaluation of a Recombinant Factor VIII Preparation (Kogenate) in Previously Untreated Patients with Hemophilia AInternational Journal of Hematology, 2003
- Use of recombinant factor IX in subjects with haemophilia B undergoing surgeryHaemophilia, 2002
- Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia AHaemophilia, 2000